장중 · Aug 17, 2026, EDT · 정보기술 · 매수

Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

[출처/시간] Briefing.com - 5:26 PM ET, 05/21/2026 TKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA submission and ongoing investigation in Phase 3 ALKAZAR trial for TKI-nave patients with advanced ALK-positive NSCLCClick here for full release.

뉴스 | admin | May 21, 2026

Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

[출처/시간] Briefing.com - 5:26 PM ET, 05/21/2026

TKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA submission and ongoing investigation in Phase 3 ALKAZAR trial for TKI-nave patients with advanced ALK-positive NSCLCClick here for full release.

Related Tags

SCHW_NEWS

3 Comments

김지나 Aug 15, 2026 at 12:25 pm ↩

리포트 잘 봤습니다. 경쟁사 비교 차트가 한눈에 들어와서 좋네요. 다음 분기 가이던스가 어떻게 나올지 궁금합니다.
장창국 Aug 16, 2026 at 12:25 pm ↩

같은 섹터의 ETF 흐름도 함께 보면 더 좋을 것 같습니다.
KRinus Aug 17, 2026 at 9:25 am ↩

의견 감사합니다. 곧 섹터 ETF 비교 차트를 별도 임베드로 추가할 예정입니다.

Related Tags

3 Comments

Leave a Comment

Related Posts